相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
Michael A. Gorin et al.
EUROPEAN UROLOGY ONCOLOGY (2022)
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J. Motzer et al.
EUROPEAN UROLOGY (2021)
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
Tim Eisen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
Axel Bex et al.
FUTURE ONCOLOGY (2019)
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D. Patel et al.
FUTURE ONCOLOGY (2019)
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
M. Gross-Goupil et al.
ANNALS OF ONCOLOGY (2018)
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial
Naomi B. Haas et al.
JAMA ONCOLOGY (2017)
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi B. Haas et al.
LANCET (2016)
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
A. Ravaud et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-α (IFN-α) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC)
Rodolfo Passalacqua et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial
JI Clark et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III study of interferon Alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An eastern cooperative oncology group/intergroup trial
EM Messing et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
